NEEDHAM, Mass. -- (BUSINESS WIRE) -- Announcing the launch of the first-ever tool in life sciences and health care to evaluate and rank new technologies and services via an end-user process. The Signature Award™, developed based on requests from the pharmaceutical and biotech industry, follows best-in-class principles to better inform decision-makers and users, investors, and those who are trying to commercialize their science.
The Signature Award program provides technology holders and service providers, from the academic and private sectors, an opportunity to present their innovations to the people who matter – the Subject Matter Experts (SMEs) who care most about new advances in their areas of specialty.
"Being a Signature Award winner has catapulted arGEN-X from believing in the uniqueness of our technology to seeing it acknowledged as such by our customers and future partners," said Debbie Allen, Ph.D, Senior Director of Business Development at arGEN-X, a past Signature Award winner.
History has proven that academics, inventors and innovators are instrumental in the advancement of the life sciences and health care. Despite their vital role, it has become increasingly difficult for these people to gain the attention of industry leaders and key opinion leaders in the scientific disciplines. Programs like this one, from Cambridge Healthtech Associates™ (CHA), bridge the gap by providing a platform that allows vendors to reach the pertinent individuals within the industry, thereby making the technology evaluation process more accessible to innovators in life sciences and health care.
Participants apply to the Signature Award program as either a commercial or an academic technology or service provider. All applicants receive qualitative and quantitative feedback from the panel of SMEs. Based on the feedback, each technology or service is placed into one of four categories defined by the strength of their value proposition and level of market readiness. Participants obtain valuable validation which can support their market penetration efforts and/or investor relations goals.
Tim Van Hauwermeiren, CEO of arGEN-X, says that “The Signature Award has enabled arGEN-X to establish the SIMPLE Antibody™ brand as the leader in tackling high value but complex antibody disease targets. We are now ideally positioned to leverage the power of our proprietary suite of antibody technologies through the creation of truly differentiated antibody products”.
CHA’s General Manager, Dawn Van Dam, explained that “the industry owes much of its progress to new science and the innovative thinkers who dedicate their lives to finding new solutions. CHA is proud to be helping the scientific community realize the potential of these contributors by providing them with a platform to receive the industry and key opinion leader feedback that they need to increase their chances of commercial success.”
Nine years ago, CHA was asked by leaders in the biopharmaceutical industry to form the Technology Evaluation Consortium™ (TEC™) and the Drug Safety Executive Council™. The launch of the Signature Award™ program is a natural progression to accommodate the growth of the TEC and the resulting demand for evaluating the vast number of technologies and services available today in life sciences and health care.
Additional information is available here and Signature Award applications can be obtained by contacting Dawn Van Dam.
About Cambridge Healthtech Associates™
Cambridge Healthtech Associates (CHA) enables clients in the life sciences and health care industries to accelerate the progression from scientific innovation to commercial success. CHA offers a refreshing, collaborative take on the standard marketing model by offering consulting, technology evaluations and marketing communication services, alongside an unparalleled understanding of industry dynamics and first-hand experience (www.chacorporate.com)
Cambridge Healthtech Associates. Transforming science into commercial success.